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Background: Nausea, vomiting and retching (NVR) was the frequently reported and 
troublesome adverse effect for patients receiving chemotherapy.  
Purpose: This study is a part of a larger study which aims to describe the NVR symptom 
experience in cervical cancer patients undergoing chemotherapy in Bali, Indonesia, and 
examine relationships with individual's risk factors.  
Method: Sixty-six patients with stage II and III cervical cancer receiving Paxus (Paclitaxel)-
Cisplatin at the second or the third cycle were enrolled. NVR was measured by the Index of 
Nausea, Vomiting and Retching (INVR) at the second day of their chemotherapy. This current 
study included only patients with age ranged between 32 to 65 years (M = 47.15, SD = 9.64, 
min-max age 35 – 65 years).  
Result:  The result showed that the NVR score was at a moderate level. Younger subjects 
(age 32-50 years old) reported significantly higher NVR scores than that of older subjects 
(age 51-65 years old) (t = 2.76, p = .007). The subjects with higher anxiety scores reported 
significantly higher NVR scores than those with lower anxiety scores (t = -2.41, p = .019). 
Subjects who had experience in motion sickness had significantly higher NVR scores (M = 
12.69, SD = 2.60) than those who did not (M = 9.23, SD = 2.86) and the difference was 
statistically significant (t = 4.98, p <.01). Meanwhile, no significant difference was found 
between subjects who reported their expectation to have nausea and those who did not (t = 
0.08, p = .94). 
Conclusion: The findings provide valuable information regarding NVR and the individual 
risk factors among patients with cervical cancer undergoing chemotherapy. Nurses should 
assess the anxiety level and a history of motion sickness of patients planned for 
chemotherapy and offer preventive interventions to prevent and control NVR occurrence and 
its distress. 
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Background 
Cervical cancer is the most common cancer in women in Indonesia (Tjindarbumi & 
Mangunkusumo, 2002; Parkin, Bray, Ferlay & Pisani, 2005), and becomes the second type of 
cancer that kills women after breast cancer (Domingo et al., 2008). Few data are available 
describing the prevalence of cervical cancer in Indonesia. Since Indonesia does not have an 
established cancer registry, Department of Health assumes cancer incidence to be 100 per 
100,000 people. Iswara, Suwiyoga, Mayura and Artha (2004) reported that cervical cancer 
represented approximately three-quarters of the gynecologic cancers. Cases of cancer in Bali 
have been found to be 29,696 cases; 55 percent of which is cervical cancer (Bali Provincial 
Health Office, 2005). From the registration record of one tertiary hospital in Bali, it is known 
that the number of patients with cervical cancer have been increasing over the years. There 
were 804 cases of cervical cancer in 2005, 1,554 cases in 2006, and the highest rate was 
2,026 cases in 2007. 
Chemotherapy is one of cancer treatments that can destroy cancerous cells and 
prevent metastasis, however it has various side effects such as nausea, vomiting and retching. 
These side effects are distressing symptoms for patients with cancer, especially those who are 
receiving chemotherapy (Bender, McDaniel, Murphy-Ende, Pickett & Rittenberg, 2002; 
Rhodes & McDaniel, 2001), and can potentially lead to patient’s refusal to continue with the 
most effective chemotherapy (Hesketh, 2000). Cohen, de Moor, Eisenberg, Ming and Hu’s 
study (2007) found that 38% of patients who received a new chemotherapy regimen 
developed acute nausea and vomiting, and 64% had delayed nausea and vomiting that highly 
related to having in the previous cycle. Liau et al. (2005) suggests that good control of acute 
chemotherapy-induced nausea and vomiting, particularly during the initial treatment received 
by chemotherapy-naïve patients, has a positive impact on the control of delayed nausea and 
vomiting.  
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The incidence and severity of nausea, vomiting and retching in patients receiving 
chemotherapy vary, depending on the type and dose of chemotherapy, combination of 
medication, and individual characteristics (Grunberg, 2004; Smeltzer, Bare, Hinkle & 
Cheever, 2008). These occur quite frequently under various conditions and can be triggered 
by different inputs or combinations of input mechanisms (Shelke, Mustian & Morrow, 2004). 
These unpleasant sensations can appear, either as a result of treatment or a disease itself and 
significantly affect quality of life of patients and compliance with therapy (Rhodes & 
McDaniel, 2001). This study presents the findings based on 66 patients with cervical cancer 
with regard to the level of nausea, vomiting, and retching and discusses the individual's risk 
factors related to NVR. 
 
Objectives  
The objectives of this study were: (1) to describe the level of NVR experience 
among cervical cancer patients undergoing chemotherapy in Bali, Indonesia, and (2) to 
examine relationships between individual's risk factors and experience of NVR among 
cervical cancer patients undergoing chemotherapy in Bali, Indonesia. 
 
Methods 
Setting 
The study was conducted at a gynecology ward, of a tertiary and referral hospital in 
eastern part of Indonesia, Bali.   This ward is third class care consists of 6-8 beds, separated 
by a curtain from each other. It provides services for the poor patients or the patients who use 
health insurance for poor people (ASKESKIN). 
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 Sample 
Sixty six (66) patients with cervical cancer receiving chemotherapy were 
recruited. The inclusion criteria included: age 30 years old or above, being at 
stage II and III of cervical cancer, being at the cycle 2 and 3 of chemotherapy: 
Paxus-Cisplatin regimen,  having nausea/vomiting in their previous cycle, 
having anxiety at mild to moderate level and no current chronic psychiatric 
condition.  
Instrumentations 
A set of questionnaires was used to collect the following data: subjects’ 
characteristics, level of anxiety and nausea, vomiting and retching. The level of 
anxiety was measured by using the Visual Analogue Scale-Anxiety (VAS-A).   
The VAS-A is a horizontal line, 100 mm in length. Patients were advised to mark on 
a line that represents their current level of anxiety. The VAS-A score was determined by 
measuring in millimeters from the left hand end of the line to the point that the patient 
marked. The scores on this VAS-A were categorized into four levels: no anxiety (0), mild 
anxiety (1-25), moderate anxiety (26-50), severe anxiety (51-75), and worst anxiety (76-100) 
(Billhult, Bergbom & Stener-Victorin, 2007). 
The Index of Nausea, Vomiting and Retching (INVR) developed by Rhodes was 
used to measure nausea, vomiting and retching. The INVR is an eight-item self-report tool. 
Each item was assigned a number based on a predefined scoring algorithm. A numeric value 
to each response was ranged from 0, the least amount of distress, to 4, the most/worst distress. 
Total symptom experience from nausea, vomiting and retching was calculated by summing 
the patient’s responses to each of the 8 items on the INVR.  The range of scores was ranged 
from 0 to 32.  The score of 0 indicated none NVR, 1-8 indicated mild NVR, 9-16 indicated 
moderate NVR, 17-24 indicated severe NVR, and 24-32 indicated worst NVR (Rhodhes & 
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McDaniel, 2001). 
Data collection 
At the second day of each subject’s chemotherapy administration, the eligible 
subjects were approached by the nurse working in the study ward. After they indicated their 
interest to participate in the study, the primary researcher or the research assistant introduced 
herself, informed about the study protocol, and obtained an informed consent. They were then 
asked to respond to the questionnaires described above. For the subjects who were unable to 
read or had vision problems, the primary researcher or the research assistant read to them 
verbatim. 
Data Analysis 
Both descriptive statistics and inferential statistics were used in this study. 
Descriptive statistics were used to describe the demographic characteristics, health-related 
characteristics and nausea and vomiting experience. Independent t-test was used for 
examining the contribution of individual risk factors (age, anxiety level, history of motion 
sickness, patient’s expectation to have nausea, and experience in receiving other 
complementary therapy) to the current experience of NVR. The assumptions of normality and 
homogeneity of variance were examined prior to the analyses and revealed no violation in all 
datasets. 
Ethical Consideration 
This study was approved by the Ethics Committee of Faculty of Nursing, Prince of 
Songkla University, Thailand and also granted for ethical clearance by the Research and 
Development Division, of a study hospital in Bali - Indonesia. The subjects received all 
necessary information related to study concerning human right issues. They were told that 
their identities would be kept secret. All the data were stored in a confidential manner and 
destroyed after the completion of the study. They could ask questions about this study and 
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had the right to withdraw from the study at any time without any consequences.  
 
Results 
The Subject’s Characteristics 
Sixty-six women with cervical cancer undergoing chemotherapy were recruited from 
gynecological ward of a tertiary hospital. The age ranged between 32 to 65 years old with the 
mean of 47 years. The majority of them were married and Hindu holders. About 53% of 
subjects had elementary school education and approximately 47% worked as farmers (Table 1).   
Table 1 
General Demographic Characteristics of the Group (N = 66) 
   
Characteristics n % 
Age (M = 47.15, SD = 9.64, min-max age 32 – 65 years) 
Younger age (32-50 years) 
 
39 
 
59 
Older age (51-65 years) 27 41 
Marital status   
Married 58 88 
Widowed 8 12 
Religion   
Hindu  54 82 
Non-Hindu  
(Buddhist/Muslim) 
12 18 
Educational level   
Elementary school 35 53 
Junior high school 16 24 
High school 13 20 
No education 2 3 
Occupation   
Farmer  31 47 
Private employee 22 33 
Housewife 13 20 
 
Considering the subjects’ health-related characteristics, about 39% subjects had 
experience in motion sickness (Table 2). Only one subject had consumed alcohol and more 
than three-quarters expected that they might have nausea (86%). Majority of the subjects had 
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moderate level of anxiety with the mean anxiety score of 35.5 (SD = 10.50, min-max 13 – 50). 
Only one subject had experienced of receiving foot massage and less than a quarter of them 
(17%) had no experience of receiving any complementary therapies. More than half of 
subjects were in the second cycle of chemotherapy (53%) and all subjects did not have co-
morbid disease.  
Table 2  
General Health-Related Characteristics of the Group (N = 66) 
   
Characteristics n % 
Experience in motion sickness   
Yes 26 39 
No 40 61 
Experience of alcohol consumption   
Yes 1 2 
No 65 98 
Expectation of nausea   
Yes 57 86 
No 9 14 
Anxiety score 
(M = 35.5, SD = 10.50, min-max 13 – 50) 
  
Mild (10-25)      10 15 
Moderate (26-50) 56 85 
Experience of receiving foot massage therapy   
Yes 1 2 
No 65 98 
Experience of receiving complementary therapy   
Yes 11 17 
No 55 83 
Cycle of Chemotherapy      
2 35 53 
3 31 47 
Stage of Cancer   
II 26 39 
III 40 61 
 
Nausea, Vomiting and Retching in Cervical Cancer Patients Undergoing 
Chemotherapy 
The patients with cervical cancer undergoing chemotherapy participating in this study 
reported having moderate NVR experience   (Table 3). 
Nausea, Vomiting and Retching of Patients with Cervical Cancer undergoing Chemotherapy  
 
Nurse Media Journal of Nursing, 2, 2, 2012, 467-481 474 
    
Table 3. 
Mean, Standard deviation, and Level of Symptom Experience of NVR (N = 66)  
Subscales Items 
on Scale 
Potential 
Range of 
Scores 
Min-Max 
scores 
Mean SD Level 
NVR Experience       
Nausea experience 4, 5, 7 0-12 4-10 7.67 1.47  
Vomiting experience 1, 3, 6 0-12 0-6 2.44 2.41  
Retching experience 2, 8 0-8 0-3 0.48 0.88  
Total NVR Score  0-32 4-16 10.59 3.23 Moderate 
 
The Relationship of Individual Risk Factors and NVR  
Independent t-Test was performed to examine whether each individual risk factors 
contributed to the NVR scores (Table 4). The findings revealed that younger subjects (age 32-
50 years old) reported significantly higher NVR scores than those of older subjects (age 51-
65 years old) (t = 2.76, p = .007). This result indicates that the older they were, the lower the 
level of nausea, vomiting, and retching they felt. Meanwhile, the subjects with higher anxiety 
scores reported significantly higher NVR scores (t = -2.41, p = .019).  These findings 
demonstrate that the more anxiety they were, the worse NVR they experienced. This study 
also revealed that the subjects who had experience in motion sickness had significantly 
higher of the NVR scores (M = 12.69, SD = 2.60) than that who did not (M = 9.23, SD = 
2.86) and the difference was statistically significant (t = 4.98, p =.00). Surprisingly, there was 
no significant difference of subjects who reported their expectation to have nausea and those 
who did not (t = 0.08, p = .94). Similarly, no significantly difference also found in the 
subjects who had experience in receiving other complementary therapy and those who did not 
(t = -1.60, p = .11). 
 
 
Nausea, Vomiting and Retching of Patients with Cervical Cancer undergoing Chemotherapy  
 
Nurse Media Journal of Nursing, 2, 2, 2012, 467-481 475 
    
Table 4 
Comparison of Individual Risk Factors and NVR Score using Independent t-Test (N = 66)  
Variables N % M SD t p value 
Age     2.76 .007 
Young age (32-50 yr) 39 59 11.46 3.08   
Old age (51-65) 27 41 9.33 3.08   
Anxiety     -2.41 .019 
Mild (1 - 25) 10 15 8.40 2.989   
Moderate ( 26 - 50) 56 85 10.98 3.136   
Experience in motion 
sickness 
 
 
  
-4.98 .000 
Yes 26 39 12.69 2.60   
No 40 61 9.23 2.86   
Expectation of nausea     
0.08 .940 
Yes 57 86 10.58 3.31   
No 9 14 10.67 2.87   
Experience of receiving 
other complementary 
therapy 
 
 
  
-1.60 .114 
Yes 11 17 12.00 3.63   
No 55 83 10.31 3.10   
 
Discussion 
In this study, patients received cisplatin agent that is one of the high risk emetogenic 
agents. The results showed that the NVR experience among cervical cancer patients 
undergoing chemotherapy in Bali, Indonesia was at a moderate level. There are several 
identified factors that might contribute to these results. Firstly, the cycle of chemotherapy 
might contribute to the severity of NVR symptoms. This current study had involved the 
patients receiving chemotherapy on the second cycle and the third cycle. The NVR symptoms 
were usually more severe on the following cycle and anticipatory nausea and vomiting 
(ANV) may develop (McRonald & Fleisher, 2005), particularly in the fourth cycle (Roscoe, 
Morrow, Aapro, Molassiotis & Oler, 2010), and was a significant predictor by cycle five 
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(Watson et al. as cited in Hickok et al., 2001). A possible explanation for the moderate level 
of the NVR scores could be due to the relatively high number of patients with cycle 2 of 
chemotherapy. Thus, the NVR scores might be less severe.  
The second factor is regarded to the combination of chemotherapy treatments. A 
previous study found that in the combined therapy (radiation and chemotherapy), subjects 
reported more symptom of distress than chemotherapy alone (Oh, 2004). Patients receiving a 
combined therapy of radiation therapy and chemotherapy experienced significantly higher 
level of symptom occurrence than those receiving chemotherapy only (Hur et al., 2002). This 
may suggest that the combination of chemotherapy is an important factor contributing to the 
symptoms experience of NVR. This present study assessed patients who received 
chemotherapy only and this might be contributed to the severity of NVR symptom. 
Thirdly, considering the severity of the disease, the stage of cancer might be another 
factor that contributes to NVR.  Patients with cervical cancer were suffered from several 
symptoms as a result of their disease or the side effects of cancer treatments. The potential 
causes of NVR in cancer patients are numerous, especially in those with advanced or 
metastatic disease (Rhodes & McDaniel, 2001). As cervical cancer progresses into more 
advanced stages, symptoms begin to appear (Yarbro, Wujcik & Gobel, 2011). Molassiotis, 
Yung, Yam, Chan and Mok (2002) stated that late stage of disease was a predictor of acute 
nausea and vomiting. A study conducted by Oh (2004) found that symptom experience was 
significantly higher in patients with advanced stage (Stages III and IV) than patients in early 
stage group. This study involved the patients at stage II and III of cervical cancer without co-
morbidity disease. Therefore, the stage of disease is suspected to contribute to the moderate 
level of NVR. 
Another factor could be related to beliefs and custom. The Balinese believe that all 
illnesses, both the physical and mental illnesses have specific causes. They believe western 
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concepts to be true within the context of certain illnesses. They also believe that illness and 
misfortune may result from laws of karmic cause and effect (Hobart, as cited in Arriaga, 
2010). Therefore, in seeking a treatment for the disease, they combine the medical treatment 
and some ritual prayer that they believed in. It makes them believe that the god will give 
whatever is the best for their family or the ill person. Therefore, the symptoms perceived will 
be lower and will resulting in the experience of the NVR. Nevertheless, research on the 
symptom experience of side effect of the cancer intervention based on cultural background in 
Indonesia, to our knowledge, virtually absent. 
Regarding individual risk factors, the findings of this study revealed that age, 
anxiety and experience in motion sickness correlated to the NVR scores. This finding 
demonstrated that older aged patients (51-65 years old) tended to tolerate chemotherapy 
better than younger patients (age 32-50 years old). This may relate to patients’ response to the 
antiemetic therapy. A study conducted by Perez (as cited in Noonan, 2005) found that older 
patients (> 50 years) have better response to antiemetic therapy compared to the younger 
patients (< 50 years). Similar to the previous study, it was found that younger adult patients 
(< 50 years old) had greater NVR than older adult patients (Watson, Meyer, Thomson & 
Osofsky, as cited in Aapro Molassiotis & Olver, 2005).  
Anxiety is a significant psychological predictor of chemotherapy-induced nausea 
and vomiting. This study showed that subjects with higher anxiety scores reported having 
significantly higher NVR scores. Similar to Adrykowski and Gregg’s study (as cited in 
Hawthorn, 1995), they found state anxiety is significantly related to both severity and 
incidence of nausea. Moreover, anxiety can be exacerbated by a prior history of nausea and 
vomiting associated with chemotherapy (Schnell, 2003).  
This study also found that experience in motion sickness had relationship with NVR 
scores. The result revealed that subjects who had experience in motion sickness had 
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significantly higher NVR scores than the subjects who did not have. The finding of this 
current study is consistent with study from Schnell, (2003). They found that patients with a 
history of motion sickness may have a lower threshold to nausea, vomiting and retching than 
the rest of the population.  
In addition, expectation was an important factor that contributes to NVR. Several 
studies stated that patients' expectation of NVR may potentiate their experience of these 
effects (Feyer et al., 2005; Liau et al., 2005; Montgomery & Bovbjerg, 2003) and can predict 
either the occurrence or the severity of common side effect such as NVR (Morrow, 1989). 
However, in this study, we found that patient expectation did not correlate with NVR scores. 
Similar result with previous study that investigated the effect of an expectancy manipulation 
designed to reduce nausea expectancy on chemotherapy-induced nausea (Shelke et al., 2008). 
They found that changing nausea expectancies possibility does not change occurrence of 
nausea. The discrepancies found between the expectation of NVR and NVR scores suggest 
that patients did not have accurate pretreatment expectations.  
Considering the experience of receiving other complementary therapy, the findings 
indicated that most patients preferred to use pharmacological therapies alone rather than 
combined with non-pharmacological therapies. This condition may be due to a lack of 
information regarding the use of complementary therapies in order to alleviate symptoms of 
chemotherapy side effects. Moreover, studies on complementary therapies in Indonesia, 
particularly Bali, are limited.  
Finally, there is a fairly wide variation in the individual patient's susceptibility to the 
development of NVR, thus there is a reasonably wide variation in the control of NVR. 
Adequate control of NVR is not often predictable within an individual patient. Some patients 
are virtually incapacitated with NVR from typically well-tolerated chemotherapeutic agents, 
while, others require only minimal anti-emetic intervention for virtually complete control. 
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Therefore, nurses should be vigilant in assessing this distressing symptom, and considering to 
patients risk factors with individually seeking. 
 
Conclusions  
In conclusion, symptom experience of NVR among cervical cancer patients 
receiving chemotherapy in Bali, Indonesia was at a moderate level. Age, anxiety and 
experience in motion sickness were individual risk factors that contributed to NVR. 
Individual risk factors are essential and statistically significantly related to the patients’ 
experience of nausea, vomiting and retching.  
 
Recommendations 
Nurses should consider individual risk factors related to nausea, vomiting and 
retching induced chemotherapy. Further study regarding to NVR in a different stage of cancer 
and different cycles of chemotherapy are needed. Another study regarding nursing 
intervention for reducing NVR in cervical cancer patients had conducted and the results will 
be discussed in the other article. 
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